Abstract | Birt-Hogg-Dubé (BHD) syndrome is an inherited renal cancer syndrome in which affected individuals are at risk of developing benign cutaneous fibrofolliculomas, bilateral pulmonary cysts and spontaneous pneumothoraces, and kidney tumours. Bilateral multifocal renal tumours that develop in BHD syndrome are most frequently hybrid oncocytic tumours and chromophobe renal carcinoma, but can present with other histologies. Germline mutations in the FLCN gene on chromosome 17 are responsible for BHD syndrome -BHD-associated renal tumours display inactivation of the wild-type FLCN allele by somatic mutation or chromosomal loss, confirming that FLCN is a tumour suppressor gene that fits the classic two-hit model. FLCN interacts with two novel proteins, FNIP1 and FNIP2, and with AMPK, a negative regulator of mTOR. Studies with FLCN-deficient cell and animal models support a role for FLCN in modulating the AKT-mTOR pathway. Emerging evidence links FLCN with a number of other molecular pathways and cellular processes important for cell homeostasis that are frequently deregulated in cancer, including regulation of TFE3 and/or TFEB transcriptional activity, amino-acid-dependent mTOR activation through Rag GTPases, TGFβ signalling, PGC1α-driven mitochondrial biogenesis, and autophagy. Currently, surgical intervention is the only therapy available for BHD-associated renal tumours, but improved understanding of the FLCN pathway will hopefully lead to the development of effective forms of targeted systemic therapy for this disease.
Introduction
Renal cell carcinoma (RCC) is not a single entity but a group of diseases originating in the kidney epithelium that are characterized by different histologies, gene alter ations, and clinical courses. 1 Substantial insight into the molecular genetics of RCC has come from studies of families with inherited renal cancer syndromes. These studies have led to the identification of the von Hippel Lindau (VHL) tumour suppressor gene mutated in the germline of patients with the inherited clear cell RCC (ccRCC) disorder, von Hippel Lindau disease, 2 and in the majority of sporadic ccRCCs. 3, 4 Subsequent RCC family studies have led to the discovery of germline acti vating hepatocyte growth factor receptor (MET) onco gene mutations in patients with hereditary papillary renal carci noma type 1, 5 and to the identification of mutations in the tricarboxylic acid cycle gene fumarate hydratase (FH) in the germline of patients with hereditary leiomyo matosis and renal cell carcinoma (HLRCC), 6 who are pre disposed to develop type 2 papillary renal tumours. In this Review, we describe the clinical presentation, molecular genetics, and management of patients with Birt-HoggDubé syndrome (BHD; OMIM 135150), a hereditary cancer syndrome caused by germline mutations in the folliculin (FLCN) tumour suppressor gene that predispose to chromophobe RCC (chRCC), hybrid oncocytic renal tumours, and renal oncocytomas. 7 In 1977, Birt, Hogg, and Dubé described small, pale, domeshaped skin tumours, "a hereditary pilar hamar toma", that appeared on the face, neck and upper torso of 15 members of a large Canadian kindred 8 at about the age of 25 years in association with trichodiscomas 9 and acro chordons (skin tags). Histologically, these lesions, termed fibrofolliculomas, consisted of specialized connective tissue surrounding an abnormal hair follicle with epithe lial strands extending into the connective tissue mantle. Hornstein and Knickenberg, 2 years earlier, had reported perifollicular fibromatosis cutis, a lesion nearly indistin guishable clinically and histologically from fibrofollicu loma, in a small twogeneration kindred. 10 The segregation pattern in these early kindreds suggested that these cuta neous fibrofolliculomas were inherited in an autosomal dominant manner, and the disease was subsequently named Birt-Hogg-Dubé (BHD) syndrome. Reports published more than a decade later noted the presence of multiple lung cysts in patients with BHD, contributing to an increased frequency of spontaneous pneumothorax that cosegregated with the cutaneous lesions. [11] [12] [13] In 1993, bilateral multifocal chRCC was reported in a BHD patient 14 and a few years later the cosegregation of renal tumours and fibrofolliculomas was identified in members of three renal cancer kindreds seen at the National Cancer Institute. 13 The association of kidney neoplasia with BHD syndrome was confirmed in a subsequent study evaluat ing the risk factors for renal tumours in 111 affected BHD patients and 112 unaffected family members.
Clinical manifestations of BHD syndrome
Cutaneous manifestations Fibrofolliculomas, trichodiscomas and acrochordons are considered the hallmark cutaneous lesions in BHD syn drome although acrochordons are not diagnostic for BHD given their frequent appearance in the general popu lation. Fibrofolliculomas are the most common pheno typic features of BHD syndrome occurring in >85% of BHD patients over the age of 25 years. [16] [17] [18] [19] These smooth, domeshaped, whitetoflesh coloured papules are 2-4 mm in diameter, and can occur singly or in numbers greater than 100 that can sometimes coalesce in a plaque ( Figure 1a) . They tend to occur on the face, neck, upper torso, and less frequently on ear lobes or oral mucosa. 13, 19 Fibrofolliculomas, which develop after puberty, are generally neither painful nor pruritic. Biopsies of these lesions reveal multiple anastomosing strands of 2-4 epi thelial cells that emanate from a central aberrant hair follicle and are frequently continuous with sebaceous glands (Figure 1b) . 13, 20 Schulz et al. 21 have suggested that trichodiscomas and fibrofolliculomas are the same lesions but sectioned in different planes, giving rise to artificial differences in histological interpretation.
Pulmonary manifestations
Patients affected by BHD syndrome are at risk of develop ing pulmonary cysts and pneumothorax. Multiple bilateral pulmonary cysts are highly penetrant manifestations in BHD syndrome, detected on high resolution CT of the chest in 70-84% of BHDaffected individuals, and occur at a median age of 30-40 years (Figure 1c,d) . 16, 17, 19, 22, 23 BHDassociated lung cysts tend to be located in the basilar and mediastinal regions of the lung, in contrast to the typical apical location of cysts in cases of primary spontaneous pneumothorax or emphysema. [24] [25] [26] Cysts that develop in patients with BHD are predominantly irregularly shaped with sharply demarcated thin walls that do not enhance on CT, and vary in size and number. [25] [26] [27] Despite the presence of pulmonary cysts, lungs of patients with BHD syndrome generally function normally or show only mild airway obstruction, but cystic lung disease can be more severe in BHDaffected individuals who are or were smokers. 25, 26 In a study of 198 patients with BHD syndrome, a sta tistically significant association between the presence of lung cysts and history of spontaneous pneumothorax was found. 24 BHDaffected individuals have a 50fold greater risk (after adjusting for age) of developing spontane ous pneumothorax than unaffected family members. 15 Approximately 30% of patients with BHD report a history of spontaneous pneumothorax, generally before the age of 40 years, with diagnoses in children as young as 7 years. 16, 17, 19, 28 Although a single episode of pneumo thorax can occur, a history of multiple pneumothoraces was reported by Toro et al. 24 in 75% of their BHD cohort (n = 198) and in 25 of 29 (86%) patients with BHD by Kunogi et al. 22 
Renal manifestations
Patients with BHD syndrome are at risk of developing bilateral, multifocal renal tumours. Renal neoplasms develop in 12-34% of individuals affected with BHD syndrome with a mean age of onset of 46-52 years (Figure 2 ), but have been reported in patients as young as 20 years. 16, 17, 29, 30, 31 The risk of developing renal tumours was sevenfold greater in BHDaffected individuals when compared with their unaffected siblings. 15 In contrast to other inherited renal cancer syndromes such as VHL (ccRCC) or hereditary papillary renal carcinoma (type 1 papillary RCC) that predispose to a single histologic tumour subtype, BHDassociated renal tumours can present with multiple histologies. The most frequent histologic tumour type in BHDaffected individuals is the hybrid oncocytic tumour (50%) with features of chRCC and renal oncocytoma. 32 Additionally, patients with BHD are at risk of developing chRCC (35%), ccRCC (9%) and, less frequently, renal o ncocytoma (5%) (Figure 3 ). [32] [33] [34] An additional feature of the kidneys of patients with BHD is the presence of renal 'oncocytosis' , 32 defined as small microscopic foci of oncocytic cells scattered throughout the normalappearing kidney parenchyma 35 that are presumed to be precursor lesions to malignant tumours. Since these foci occur in the kidneys of BHD patients regardless of their tumour histology, it has been suggested that renal oncocytic cells might be precursors of the various histological subtypes of BHDassociated renal tumours. 32 Other manifestations A number of other clinical features have been reported in patients with BHD including lipomas, 12, 13, 16, 19 para thyroid adenomas, 12, 19 thyroid nodules, 19 thyroid cancer, 17, 22 and parotid oncocytomas, 16, 17, [36] [37] [38] but whether these are incidental findings or true phenotypic features of BHD s yndrome is unclear.
Early case reports linked the presence of colon polyps and/or colorectal cancer with BHD syndrome, 10, 11, 31, 39, 40 but a risk assessment performed in 111 BHDaffected patients seen at the National Institutes of Health did not find a significant increase in colonrelated manifesta tions when patients with BHD were compared with their 112 unaffected siblings. 15 By contrast, the risk of develop ing colonic neoplasms assessed in 149 patients with BHD in a University of Birmingham study was found to be 20% by age 80 years compared with 4.9% in the general UK population. 41 Differences in environmental exposures or genetic modifiers in the two cohorts might also contribute to these divergent results and will require additional study to confirm or refute a link between colon neoplasia and BHD syndrome.
Diagnostic criteria for BHD syndrome BHD syndrome can be phenotypically heterogeneous within members of a family or between families with the same FLCN mutation (Figure 4 ). Any combination of the cutaneous, pulmonary, or renal manifestations in an individual or multiple members of a family with BHD can be considered part of the phenotypic spec trum. Thus, the following diagnostic criteria, alone or in combi nation, are suggestive of BHD syndrome: ≥2 cuta neous papules clinically consistent with fibro folliculoma and/or trichodiscoma and ≥1 histologically confirmed fibrofolliculoma; multiple bilateral pulmonary cysts located mainly in the basilar regions of the lung with or without a history of spontaneous pneumothorax that develops before 40 years of age, but especially with a family history of these pulmonary manifestations; bilat eral, multifocal chRCC or hybrid oncocytic tumours especially with a family history of renal tumours or early age (<50 years) of onset; a combination of these cutaneous, pulmonary or renal manifestations present ing in a patient or members of their family. A definitive diagnosis of BHD syndrome is confirmed with a diag nostic genetic test that is positive for a germline FLCN mutation (Box 1).
Molecular genetics of BHD syndrome
The FLCN gene In 1998, a rare genetic disorder, termed familial renal oncocytoma (FRO), was described, 42 in which individ uals within a family presented with multiple bilateral renal oncocytomas. Further evaluation of these patients resulted in the identification of cutaneous facial papules that, when biopsied, were found to be consistent with fibrofolliculomas. 13 Recruitment of additional families affected by BHD provided the basis for genetic linkage analysis, which led to mapping of the disease locus to chromosome 17p11.2 43, 44 and the subsequent cloning of a novel gene, FLCN, which was found to be mutated in the germline of BHDaffected individuals. 7 A FLCN exon 11 insertion/deletion mutation in a tract of eight cytosines (c.1285dupC or c.1285delC) was reported by Nickerson et al. 7 in 44% of their BHD patient cohort and seems to be a mutation 'hot spot' in other cohorts as well. [16] [17] [18] 29, 30 To date, 149 unique FLCN germline mutations spanning all 14 exons have been identified in BHD syndrome and familial spontaneous pneumothorax families, and cata logued in the Leiden Open Variation Database. 45, 46 They are predominantly mutations (insertion/deletion, non sense, splice site) that result in premature protein trunca tion and presumed loss of FLCN function. In addition, nine large intragenic deletions or duplications expected to severely disrupt protein structure or, at a minimum, to delete the last exon ( Figure 5) , 22 mutations 46 resulting in amino acid substitutions, and two mutations that affect the initiator codon 46 have been documented. Nahorski et al. 49 evaluated four of these FLCN missense mutations and found that p.Arg239Cys and p.His255Pro FLCN mutants demonstrated reduced protein stability in vitro and the latter mutation sup ported colony formation in soft agar, whereas p.Val400Ile and p.Lys508Arg mutant proteins demonstrated stability similar to wildtype FLCN and suppressed anchorage independent growth in vitro. Additional biochemical studies are needed to confirm the pathogenicity of the FLCN missense mutations reported in patients with BHD. New technologies including highthroughput sequencing and multiplex ligationdependent probe amplification (MLPA) have improved the ability to detect sequence variants and large deletions/duplica tions resulting in FLCN mutation detection rates that approach 90%. 16, 17, 29 Genotype-phenotype correlations To date, no clear correlation between type of mutation or location within the FLCN gene and any of the pheno typic manifestations has been identified, although some interesting trends have been noted. [16] [17] [18] 29 FLCN muta tions seemed to occur more frequently (23/30) in the 3' end of the gene in a Japanese BHD cohort in which lung cysts and history of pneumothorax were the predomi nant phenotypic features. 22 In support of this associ ation, Toro et al. 24 showed a trend toward more episodes of pneumothorax in BHD patients with FLCN mutations in exons 9 and 12, and a statistically significant association between mutations in exon 9 and a greater number of lung cysts. Another report by Schmidt et al. 16 noted that BHDaffected individuals with the c.1285delC muta tion in the exon 11 mutation hot spot had fewer renal tumours (1/26) compared with BHDaffected individ uals with the c.1285dupC mutation (13/56), although the sample size was too small for significance and this result was not replicated in a study of another 50 families with BHD conducted by the same institution. 17 Although Zbar et al. 15 did not find a significantly greater risk for colorectal neoplasia in a U.S. BHD cohort, a University of Birmingham study in the UK compared patients with BHD who had two recurrent FLCN muta tions and found a significantly higher risk of colo rectal neoplasia in patients with the c.1285dupC mutation (n = 37) versus the c.610delGCinsTA mutation (n = 32; χ 2 = 5.78, P = 0.016). 41 These findings raise the possibility that different allelic variants of FLCN might predispose to a greater or lesser risk of colon neoplasia in BHD syn drome. FLCN insertion/deletion mutations in the exon 11 C 8 tract have also been reported in 16-23% of spora dic colorectal tumours with demonstrated micro satellite instability (MSI) 41, 50 suggesting that the p olycytosine tract in FLCN might be an effective target of MSI.
FLCN mutation and loss of tumour suppression FLCN is a novel tumour suppressor gene that fits the twohit model for tumour suppression. 51 In addition to an inactivating germline FLCN mutation, Khoo et al. 31 identified a somatic 'second hit' FLCN mutation in a chromophobe renal tumour from a patient with BHD. Vocke et al. 52 found somatic FLCN mutations (predomi nantly frameshift mutations) in 53% of 77 renal tumours from BHDaffected patients harbouring germline FLCN mutations, and loss of heterozygosity on chromo some 17p in 17% of the remaining tumours ( Figure 6 ). Naturallyoccurring canine and rat models of BHD syn drome also develop kidney tumours as a consequence of inheriting germline mutations in the FLCN homologue with subsequent loss of the remaining FLCN allele in the tumours. 53, 54 Yang et al. 55 established a cell line from a BHD associated renal tumour that carries only the germline FLCN mutation of the patient from which it was derived, indicating that the tumour had lost the wild type FLCN allele. This cell line was tumorigenic in immunocom promised mice, 55, 56 but lost its tumorigenic properties when the normal copy of FLCN was restored. 56 Further support for FLCN as a tumour suppressor is provided by Hudon and colleagues, 57 who showed that FLCN knock down in the ccRCC cell line ACHN resulted in formation of signifi cantly larger tumours in athymic nude mice, whereas overexpression of FLCN in 786O cells-which are deficient in the tumour suppressor VHL and tumori genic in vivo-led to a decrease in VHLdeficient xeno graft growth. 57 Taken together, these data emphasize a tumour suppressor function for FLCN in normal kidney cells and demonstrate loss of tumour suppression when FLCN is inactivated in vivo. Nature Reviews | Urology 
Paucity of FLCN mutations in sporadic tumours
The VHL gene that is mutated in the germline of patients with ccRCC who have the inherited multisystem dis order von HippelLindau disease 2 is also inactivated by mutation, hypermethylation or loss in >90% of sporadic clear cell kidney cancer. 4, 58 These findings led investiga tors to evaluate sporadic renal tumours, especially those with chromophobe and oncocytic histologies, for FLCN mutations. However, very few FLCN mutations were found in these tumours. FLCN mutations were identi fied in 5/46 chromophobe renal tumours (although 3/5 were likely germline) and 1/18 renal oncocytomas by Gad et al. 59 Khoo et al. 60 found only one FLCN mutation (lacking matched normal) in 39 sporadic renal tumours and Fernandez da Silva et al. 61 found only two missense mutations in 30 sporadic renal tumours and cell lines, whereas Nagy et al. 62 found no mutations in 16 chromo phobe tumours and renal oncocytomas. A 2014 report from The Cancer Genome Atlas (TCGA) project con firmed the absence of FLCN mutations in 66 sporadic chromophobe renal tumours by whole exome sequenc ing. 63 Taken together, these findings would suggest that somatic FLCN mutations have only a minor role in the development of sporadic counterpart renal tumours.
FLCN function and interacting proteins

FLCN and FNIP1
Following the cloning of the FLCN gene and identifi cation of diseasecausing mutations in the germline of BHD families, efforts were focused on elucidating FLCN protein function to better understand how loss of function leads to kidney cancer, fibrofolliculomas and pulmonary cysts. The first protein-protein interaction studies led to the identification of a novel FLCN inter acting protein, folliculininteracting protein 1 (FNIP1), which interacts with the carboxy terminus of FLCN and with 5'AMPactivated protein kinase (AMPK), an important energysensing enzyme that monitors cellular energy status and is a negative regulator of mechanistic target of rapamycin (mTOR), the master controller of protein synthesis and cell growth. 64, 65 These and sub sequent studies demonstrated that FLCN could exist in multiple phosphorylated forms, which were differentially affected by FNIP1 binding and by inhibitors of AMPK and mTOR. 64, 66 FLCN and FNIP2 A second FLCN interacting protein, folliculin interacting protein 2 (FNIP2), 67 also referred to as FNIPL 68 or MAPO1, 69 was identified by bioinformatics searches for FNIP1 homologous proteins. FNIP2 has 49% homo logy with FNIP1 and, like FNIP1, binds to the carboxy terminus of FLCN and interacts with AMPK. 67 FNIP1, FNIP2 and FLCN can form homoduplexes and hetero duplexes, suggesting that FNIP1 and FNIP2 might work cooperatively with FLCN, or independently. Based on tissue specific expression of one compared to the other, it is possible that their functions could be unique in some tissues, but both FNIP1 and FNIP2 are similarly expressed in the kidney suggesting potential functional redundancy. 67 Evidence for overlapping growth suppres sive functions for FNIP1 and FNIP2 in kidney was pro vided by the fact that kidneytargeted Fnip1/Fnip2 double knockout mice developed enlarged polycystic kidneys, and Fnip1 heterozygous/Fnip2 homozygous knockout mice developed kidney tumours, whereas neither Fnip1 knockout mice nor Fnip2 knockout mice demonstrate a kidney phenotype. 70, 71 These findings point to redundant roles for FNIP1 and FNIP2 in their interaction with the FLCN tumour suppressor pathway in the kidney. An addi tional putative function for Fnip1 in Bcell development is supported by the finding that Bcell defective phenotypes developed in two independent Fnip1 knockout mouse models 70, 72 although to date no related Bcell phenotypes have been reported in patients with BHD syndrome.
Potential pathways in BHD tumorigenesis
Modulation of the AKT-mTOR pathway Initial clues to understanding FLCN function were obtained from studies of a number of Flcndeficient animal models. Kidneytargeted inactivation of Flcn in a mouse model using Cre-lox technology produced a multicystic kidney phenotype that led to renal failure and shortened lifespan, and displayed activation of the RACα serine/threonineprotein kinase (AKT)-mTOR pathway in the cystic kidneys. This phenotype was markedly reduced by treatment with the mTOR inhibi tor rapamycin. 73, 74 Heterozygous Flcn knockout mice develop lateonset solid renal tumours with histologies similar to human BHD tumours 75, 76 and show loss of the wildtype Flcn allele. 75 Hasumi et al. 75 showed that Figure 4 | Phenotypic heterogeneity in a family affected with Birt-Hogg-Dubé (BHD) syndrome. A BHD kindred in which affected family members who inherit the same germline mutation present with different phenotypes. Although person I-1 was clearly a carrier of the mutation, his DNA was not available for testing, so his mutation status was not determined.
Box 1 | Diagnostic criteria for Birt-Hogg-Dubé syndrome
Diagnostic criteria suggestive for BHD syndrome ■ ≥2 cutaneous papules clinically consistent with fibrofolliculoma and/or trichodiscoma and ≥1 histologically confirmed fibrofolliculoma ■ Multiple bilateral pulmonary cysts located mainly in the basilar regions of the lung with or without a history of spontaneous pneumothorax that develops before age 40 years, but especially with a family history of these pulmonary manifestations ■ Bilateral, multifocal chromophobe renal carcinomas or hybrid oncocytic tumours, especially with a family history of renal tumours or diagnosed at <50 years of age ■ A combination of these cutaneous, pulmonary or renal manifestations presenting in the patient or members of his family Diagnosis of BHD is confirmed by a diagnostic genetic test that is positive for a germline FLCN mutation by DNA sequencing.
Flcn
+/-mouse tumours as well as renal tumours from BHDaffected patients displayed activated AKT, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2), supporting a role for FLCN in downregulating the AKTmTOR pathway. On the other hand, Hartman et al. 76 demonstrated reduced mTOR activity in Flcn +/ spontane ous renal tumours, and in renal tumours with reduced latency that developed in a Flcnheterozygous mouse model subjected to N-ethylNnitrosourea (ENU) muta genesis, in agreement with in vitro FLCNknockdown cell line results and yeast homologue bhd mutant data from the same group. 77 In a third Flcnheterozygous model, both mTOR activation (elevated phosphoS6 in large cysts) and mTOR inactivation (reduced phosphoS6 in small cysts) were observed. 57 The conflicting results pre sented in these in vitro and in vivo systems have led to the hypothesis that the effect of FLCN deficiency on mTOR activation or inhibition might depend on the cell type or context in which it occurs (Figure 7) . mTOR activation by amino acids through Rags mTORC1 is a master regulator of cell growth and senses the energy and nutrient needs of the cell to regulate ana bolic and catabolic processes. Emerging evidence has shown that mTORC1 senses and is activated by amino acids at the lysosome surface through a multimeric protein complex that includes the Rasrelated GTP binding (Rag) family of GTPases (RagA/B and RagC/D), whose bound nucleotide state (GDP/GTP) determines the recruitment of mTORC1 to the lysosome. 78 Tsun et al. 79 have shown a role for FLCN, in complex with FNIP1/2, as a GTPase activating protein (GAP) for RagC/D. GDP loading of RagC/D facilitates mTORC1 binding to the lyso some for activation in an aminoacidsensitive manner. Evidence by Petit et al. 80 also supports a role for FLCN in aminoacid dependent mTORC1 activation on the lysosome surface by a somewhat different mechanism. Their findings support a role for FLCN with protein partner, FNIP1, acting as a guanine exchange factor (GEF) for RagA (and predicted for RagB), which results in GTP loading of RagA/B and recruitment and activation of mTOR. Recently the crystal structure of the carboxy terminus of FLCN was solved and was found to be distantly related to differentially expressed in normal cells and neoplasia (DENN) proteins that are characterized by their Rab GEF function. 81 Nookala et al. 81 were able to show in vitro that FLCN had GEF activity against another Rab GTPase, Rab35. Together these studies provide strong support of a role for FLCN in facilitating mTOR activation at the lyso some surface in an aminoacidsensitive manner via the Rasrelated GTPases (Figure 7) .
However, these studies do raise the question of why FLCN, a tumour suppressor, is a positive effector of the mTOR pathway. One idea put forth in both of these reports is that suppression of mTORC1 activity resulting from FLCN deficiency might push other pathways into overdrive that could more than compensate for mTOR inhibition. Additional studies will be necessary to clarify the mechanistic details involved in modulation of mTOR signalling by the FLCN-FNIP complex.
TFE3/TFEB transcriptional activation
The first evidence that FLCN controlled the transcrip tional activity of basichelixloophelix transcription factor E3 (TFE3), a member of the microphthalmia tran scription (MiT) family, was reported by Hong and col leagues 82 who showed that TFE3 was sequestered in the cytoplasm by FLCN, but under FLCN deficiency, TFE3 moved to the nucleus where it became transcriptionally active. They demonstrated that TFE3 nuclear localization was correlated with decreased TFE3 phosphorylation and increased activity in a number of FLCNdeficient human and mouse renal tumours and cell lines. Petit et al. 80 investigated FLCNfacilitated TFE3 phosphorylation in more detail. Earlier work from this group demonstrated that mTORC1dependent phosphorylation of the MiT family member transcription factor EB (TFEB) at serine 211 triggered its interaction with 1433 proteins, thereby preventing nuclear accumulation when the lysosome was functioning efficiently. 83 In later work they showed that FLCN and its interacting partner FNIP1 were required for mTOR recruitment to the lysosome for amino acid stimulated activation, and that mTORdependent TFEB phosphorylation at serine 211 was diminished and nuclear localization of TFEB was enhanced in FLCNknockdown cells. 80 Taken together, these studies support a role for FLCN in regulating TFE3 and/or TFEB transcriptional activity through mTORdependent p hosphorylation of these transcription factors.
Finally, Betschinger et al. 84 performed a functional screen of mouse embryonic stem cells (ESC) to identify genes required for exit from groundstate pluripotency to cell lineage differentiation. In further support of a role for FLCN in controlling TFE3 transcriptional activ ity, they found that Flcn, in complex with both binding partners Fnip1 and Fnip2, drives ESC differentiation by cytoplasmic sequestering of Tfe3, thereby inhibiting transcriptional activation of the Tfe3 target gene, Esrrb, an orphan nuclear receptor and central pluripotency factor (Figure 7 ).
Cell-cell adhesions and RhoA signalling
Two independent studies using yeast hybrid screens have identified p0071 (plakophilin4) as a FLCN interacting protein. This armadillo repeatcontaining protein binds Ecadherin at adherens junctions, which are important for maintenance of cell architecture in epithelial tissues, and regulates ras homologue family member A (RhoA) activ ity in the cytoplasm. 85 FLCN loss resulted in increased cell-cell adhesion, disruption of cell polarity and dys regulated RhoA signalling. 86, 87 Increased cell-cell adhe sions were reported in FLCNdeficient lung cell lines in vitro, 88 and marked reduction in Ecadherin expression at adherens junctions and increased alveolar apoptosis were observed in lungs of mice with lungtargeted Flcn inactivation. 89 These findings support a role for FLCN in maintaining critical cell-cell adhesions, which preserve lung and kidney epithelial cell integrity.
Additional pathways in which FLCN interacts
Recent reports support a role for FLCN in other cancer associated pathways. Using a gene expression microarray approach, Hong et al. 56 demonstrated downregulation of genes involved in transforming growth factor β (TGFβ) activation and signalling in FLCNdeficient in vitro and in vivo models, including BHDassociated renal tumours. Using Flcndeficient mouse ESCs, Cash et al. 90 found defects in cellintrinsic apoptosis that correlated with reduced TGFβmediated transcription of the pro apoptotic Bcl2 homology domain 3 (BH3)only gene Bim (also known as Bcl2l11); Bim (Bcl2like protein 11) expression was also downregulated in BHD renal tumours. These studies provide support for a role of FLCN in regulation of TGFβ signalling ( Figure 7) .
Several reports have identified FLCN functions in autophagy. Possik et al. 91 observed that loss of Flcn in a Caenorhabditis elegans model led to constitutive AMPK activation and induction of autophagy. However, Dunlop et al. 92 showed that autophagy was impaired in FLCN deficient kidney cell lines and BHD renal tumours. This report supports a mechanism by which FLCN, regulated by ULK (unc51 like autophagy activating kinase 1) and in complex with FNIP1/2, positively regulates autophagy through interaction with GABARAP (GABA(A) receptor associated protein), a component of the autophagosome machinery. Interaction of FLCN in TGFβ signalling and autophagy pathways suggests a fundamental role for FLCN in maintenance of cellular homeostasis (Figure 7) .
Managing patients and their families
Surveillance of at-risk BHD family members Individuals are at risk for developing renal tumours if they or their family members present with manifesta tions of BHD syndrome, including fibrofolliculomas or pulmonary cysts with or without a history of spontane ous pneumothorax, a family history of bilateral, multi focal, hybrid oncocytic or chromophobe renal tumours, or if they test positive for a germline FLCN mutation. As renal tumours have been reported in BHDaffected family members as young as 20 years of age, 30,31 diagnostic genetic testing for FLCN is recommended with informed consent starting at 20 or 21 years of age. 93, 94 Atrisk BHD affected family members are recommended to undergo abdominal imaging at least every 36 months, and life long surveillance is warranted. Renal ultrasono graphy might not detect small or isoechoic hybrid oncocytic and chromophobe tumours, 95 so abdominal CT or MRI with intravenous contrast is recommended to provide the best anatomical detail of the kidney and distinguish solid and cystic lesions. MRI is often preferred for long term surveillance in order to reduce patients' radiation exposure. 93 Once a renal mass is detected, imaging inter vals are d etermined by the size and growth rate of the renal tumours. Nature Reviews | Urology 
Management of BHD-associated renal tumours
Renal tumours that develop in the setting of BHD syn drome are most commonly hybrid oncocytic tumours and chRCC, which tend to be more indolent than, for example, the ccRCC that occurs in the setting of VHL disease or the type 2 papillary renal tumours character istic of HLRCC. [96] [97] [98] Thus, patients are managed by active surveillance until the largest tumour reaches the 3 cm threshold. At that point, nephronsparing surgery is rec ommended. Patients with BHD are at risk of develop ing bilateral, multifocal renal tumours and can require multiple surgeries during their lifetime; it is impor tant, therefore, to use surgical procedures that preserve renal function whenever possible. Generally, very small margins of normal kidney parenchyma are taken during tumour enucleation of more indolent BHD tumours; however, wider margins can be used for renal tumours with more aggressive histology, such as ccRCC. Other factors such as tumour growth rate, size and location can affect the appropriateness of the '3 cm rule' for surgical intervention. Prior to surgery, pulmonary assessment should be performed to evaluate the presence of pulmo nary cysts, and excessive intraoperative positive pressure ventilation should be avoided to reduce the chance of a cyst rupture leading to a possible pneumothorax. 93, 33 In cases where tumours measuring >3 cm are detec ted in both kidneys, staged surgical procedures are rec ommended. Surgery on the kidney requiring the least invasive resection might be performed first, followed by surgical management of the contralateral kidney only after co mplete recovery from the initial surgical procedure. 93 Although it has been suggested that ablation methods such as radiofrequency ablation (RFA) or cryoablation therapy could be appropriate for small renal tumours, 93 our experience is that these procedures are not recom mended in healthy BHDaffected patients who are good surgical candidates. Patients with BHD will often have multiple lesions that require extensive surgical interven tion to remove all accessible tumours; previous ablation can complicate subsequent surgical procedures and also can make postablation imaging difficult to inter pret. 93, 99, 100 However, cryotherapy or ablative procedures can be good options for elderly patients or those with comorbidities that would preclude surgical intervention.
As BHDaffected patients tend to develop indolent types of renal tumours, including hybrid oncocytic tumours and chRCC, metastases are seen less often in BHD syndrome than, for example, in VHL disease, in which patients are at risk of developing clear cell renal tumours that are aggressive and likely to metastasize. Benusiglio et al. 30 reported metastases in four of a cohort of 33 BHDaffected patients, but only one died, and of an unrelated cause. In contrast, five of 14 patients with BHDassociated renal tumours described by Houweling et al. 29 developed metastases, four of whom died within 1 year of diagnosis despite surgical, radio logical, chemo therapeutic, and/or immuno therapeutic treatments ( Table 1 ). Two of 10 BHD patients with renal tumours reported in a study by Pavlovich et al. 33 developed metasta ses and died. In these and other cases where metastases led to patient mortality, the predomi nant tumour histology was the more aggressive clear cell type, 29, 31, 33, 101 in contrast with the more indolent chromo phobe and hybrid tumours that developed in the m etastatic cases reporting longerterm survival. 30 Differential diagnosis of BHD tumours The ability to distinguish BHDassociated renal tumours from sporadic hybrid oncocytic and chromo phobe renal tumours is important. Thus, there is a need to develop biomarkers for the differential diagnosis of BHD associated tumours and their sporadic counterparts. In that regard, Hong et al. 82 discovered that the expres sion of glycoprotein nonmetastatic B (GPNMB), a tran scriptional target of TFE3, was high in FLCNdeficient kidney tumours from patients with BHD as well as in tumours, and compared GPNMB expression with that of sporadic counterpart tumours. They observed strong GPNMB staining in the BHD chromophobe and onco cytic hybrid tumours, but none or minimal staining in the corresponding spora dic tumours, suggesting that GPNMB might serve as a biomarker to distinguish BHD and sporadic hybrid oncocytic and chromophobe renal tumours, and could potentially provide a t herapeutic target for treatment of BHDassociated renal cancer. Both BHDassociated and sporadic renal onco cytomas and chRCC are characterized by the presence of large numbers of mitochondria. 33, 102 Sporadic renal oncocytomas are associated with somatic mutations in mitochondrial DNA (mtDNA) that inactivate subunits of mitochondrial complex I of the electron transport chain, 103 but no mtDNA sequencing data have been reported for BHDassociated renal oncocytomas. Klomp et al. 104 performed gene expression microarray analysis of BHDassociated renal oncocytomas and chRCC and found clear genetic differences from sporadic counter part tumours. Specifically, BHDassociated tumours lacked the chromosomal abnormalities typically seen in sporadic renal oncocytoma (loss of chromosome 1 or chromosome 11q13 translocation) and chRCC (losses of chromosomes 1, 2, 6, 10 and 17). Importantly, although both BHD and sporadic counterpart tumours exhibited a prominent mitochondrial gene expression phenotype, BHDassociated tumours displayed a unique upregula tion of two transcription factor genes involved in mito chondrial biogenesis, PGC1α /PPARGC1A (peroxi some proliferatoractivated receptor γ, coactivator 1 α) and TFAM (transcription factor A, mitochondrial). A clear inverse correlation between FLCN expression and a set of genes known to be transcriptionally activated by PGC1α was also observed. 104 Two studies from the same group 105, 106 have confirmed that loss of FLCN leads to upregulation of PGC1α /PPARGC1A expression in BHDassociated kidney tumours, a BHD renal tumour cell line, and Flcndeficient murine kidney, heart, and muscle tissues. Taken together these data suggest that a unique FLCN-PGC-1α-TFAM signalling axis exists in BHDassociated renal tumours that might be absent from the sporadic counterpart tumours and could be useful in the differential diagnosis of BHDassociated tumours from their sporadic counterparts.
Potential therapeutic options for BHD
The longterm goal of the efforts that led to the identifi cation of the gene for BHD (FLCN) is focused on eluci dating the mechanistic details of the FLCN pathway to provide a foundation for the development of an effec tive form of therapy for patients with metastatic as well as localized BHDassociated kidney cancer, cutane ous fibrofolliculomas, and pulmonary cysts. Although the development of advanced disease is uncommon in BHD, BHDassociated renal tumours are malignant and can metastasize, and there are currently no approved therapeutic options available. To date, the FDA has approved seven agents that target the VEGF and mTOR pathways (sorafenib, sunitinib, temsirolimus, bevaci zumab, everolimus, pazopanib, and axitinib) for treat ment of metastatic RCC. However, only a few cases of metastatic chRCC have been described in the literature, and experimental evidence for the use of VEGF and mTOR pathway inhibitors in this histological subtype is lacking. Shuch et al. 107 summarized four case reports of Abbreviation: NA, not available.
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patients with sporadic metastatic chRCC who had pro gressed on VEGF inhibitors sorafenib or sunitinib, but continued to have stable disease 1-4 years after initiating mTORpathway targeted therapy. Everolimus provided a longer lasting effect than VEGF inhibitors against meta static papillary RCC in a BHDaffected patient reported by Nakamura and coworkers. 108 Treatment with the mTOR inhibitor rapamycin resulted in partial regression of the earlyonset multicystic kidney phenotype of two pre clinical Flcndeficient animal models, 73, 74 although whether this model is an accurate representation of the mTOR status of BHDassociated solid tumours is contro versial. Given the conflicting data concerning whether FLCN is a positive or negative regulator of mTOR, clinical trials will be needed to determine the efficacy of agents which inhibit the mTOR pathway in patients with BHDassociated RCC.
In addition to targeting the mTOR pathway, studies have uncovered other potential targets and therapeu tic approaches for BHDassociated renal cancer that are being pursued. Using the COMPARE algorithm to analyse public data on FLCN expression and response of the NCI60 cancer cell line panel to anticancer drugs, Lu et al. 109 identified mithramycin (also known as plicamycin) as 10fold more cytotoxic against the BHDassociated renal tumour cell line UOK257 when compared with the FLCNrestored companion line. Human Flcndeficient UOK257 cells treated with mithra mycin were growth arrested in the S and G2-M phases of the cell cycle, and this effect was enhanced by low dose rapamycin. In a subsequent study by the same team, 110 a syntheticlethal screen, using an approach based on a phosphatase small interfering RNA library, revealed that knockdown of protein phosphatase Slingshot homo logue 2 (SSH2) induced caspase3/7 activation and apop totic death in FLCNdeficient human cell lines but not FLCNrestored counterpart lines.
Work by Preston et al. 111 has suggested another poten tial target pathway in BHD. These researchers have shown high levels of hypoxiainducible factor (HIF) activity and its transcriptionally upregulated genes in FLCNdeficient renal tumour cell lines under both hypoxia and normoxia, effects reversed by reexpression of FLCN. Evaluation of the metabolic profile of these cells revealed a shift under FLCN deficiency to aerobic glycolysis (the socalled Warburg effect) with a depen dency on glucose. Findings in a followup study by these researchers suggest that FLCN loss leads to activation of AMPK resulting in increased PGC1α, upregulated mitochondrial biogenesis, and increased reactive oxygen species (ROS) production leading to elevated HIF tran scriptional activity, thereby driving Warburg metabolic reprogramming. 112 In their earlier study, Preston et al. 111 were able to inhibit growth of FLCNdeficient tumour cells by blocking glycolysis with 2deoxyglucose, sug gesting that targeting the glycolytic pathway could be a potential therapeutic approach for treatment of BHD syndrome. The results reported in these studies support the need for followup research efforts to pursue these potential novel targets for BHDassociated renal cancer.
Conclusions
The clinical phenotype in BHD syndrome is now very well characterized, and the hybrid oncocytic tumours that develop in the setting of BHD are unique among heredi tary renal cancer syndromes. In the decade or more since the cloning of the FLCN gene, we have obtained a broader understanding of the function of this tumour suppressor and how inactivation of FLCN drives the development of BHDassociated renal tumours, cutaneous fibro folliculomas and pulmonary cysts. Interacting proteins FNIP1 and FNIP2 have been identified that link FLCN to mTOR through AMPK, and evidence supporting a role for FLCN in modulating the AKT-mTOR pathway is accumulating, although the question of whether FLCN is involved in mTOR activation or inhibition might be related to cell type or context. A role for FLCN in other pathways and cell processes known to be deregulated in cancer is supported by work from a number of research labs. Currently, surgical intervention is the only therapy available to patients with BHDassociated renal tumours. Development of effective targeted therapies will depend on a more detailed understanding of the primary path ways in which FLCN functions as a tumour suppressor, which, when deregulated under FLCN deficiency, might drive renal tumorigenesis.
